Breaking News, Collaborations & Alliances

Hemispherx Enters Agreement With myTomorrows

Will focus on early access program for rintatolimod in Europe

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hemispherx Biopharma Inc. has formed an agreement with Impatients N.V., a Netherlands-based company doing business as myTomorrows, for the commencement and management of an early access program (EAP) in all of Europe and Turkey. myTomorrows, as Hemispherx’ exclusive service provider in Europe and Turkey, will perform EAP activities in Europe and Turkey to include the supply of rintatolimod for the treatment of chronic fatigue syndrome (CFS) to patients with an unmet medical need. &#8...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters